JP2018506555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506555A5 JP2018506555A5 JP2017544887A JP2017544887A JP2018506555A5 JP 2018506555 A5 JP2018506555 A5 JP 2018506555A5 JP 2017544887 A JP2017544887 A JP 2017544887A JP 2017544887 A JP2017544887 A JP 2017544887A JP 2018506555 A5 JP2018506555 A5 JP 2018506555A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- receptor
- receptor agonist
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562120726P | 2015-02-25 | 2015-02-25 | |
| US62/120,726 | 2015-02-25 | ||
| PCT/US2016/019368 WO2016138138A1 (en) | 2015-02-25 | 2016-02-24 | 5ht agonists for treating disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081127A Division JP2020143087A (ja) | 2015-02-25 | 2020-05-01 | 障害を治療するための５ｈｔ作動薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506555A JP2018506555A (ja) | 2018-03-08 |
| JP2018506555A5 true JP2018506555A5 (enExample) | 2018-04-19 |
| JP6884703B2 JP6884703B2 (ja) | 2021-06-09 |
Family
ID=56789223
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544887A Active JP6884703B2 (ja) | 2015-02-25 | 2016-02-24 | 障害を治療するための５ｈｔ作動薬 |
| JP2020081127A Pending JP2020143087A (ja) | 2015-02-25 | 2020-05-01 | 障害を治療するための５ｈｔ作動薬 |
| JP2021128790A Active JP7846506B2 (ja) | 2015-02-25 | 2021-08-05 | 障害を治療するための５ｈｔ作動薬 |
| JP2022091363A Pending JP2022116307A (ja) | 2015-02-25 | 2022-06-06 | 障害を治療するための５ｈｔ作動薬 |
| JP2023169390A Pending JP2024009839A (ja) | 2015-02-25 | 2023-09-29 | 障害を治療するための５ｈｔ作動薬 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081127A Pending JP2020143087A (ja) | 2015-02-25 | 2020-05-01 | 障害を治療するための５ｈｔ作動薬 |
| JP2021128790A Active JP7846506B2 (ja) | 2015-02-25 | 2021-08-05 | 障害を治療するための５ｈｔ作動薬 |
| JP2022091363A Pending JP2022116307A (ja) | 2015-02-25 | 2022-06-06 | 障害を治療するための５ｈｔ作動薬 |
| JP2023169390A Pending JP2024009839A (ja) | 2015-02-25 | 2023-09-29 | 障害を治療するための５ｈｔ作動薬 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10874643B2 (enExample) |
| EP (4) | EP3632434A1 (enExample) |
| JP (5) | JP6884703B2 (enExample) |
| KR (3) | KR102385665B1 (enExample) |
| CN (2) | CN113546174A (enExample) |
| AU (3) | AU2016222804C1 (enExample) |
| BR (1) | BR112017018297B1 (enExample) |
| CA (2) | CA2977135C (enExample) |
| CY (1) | CY1125360T1 (enExample) |
| DK (1) | DK3261640T3 (enExample) |
| EA (2) | EA201992474A3 (enExample) |
| ES (2) | ES3060954T3 (enExample) |
| HR (1) | HRP20220822T1 (enExample) |
| HU (1) | HUE059559T2 (enExample) |
| LT (1) | LT3261640T (enExample) |
| PL (1) | PL3261640T3 (enExample) |
| PT (1) | PT3261640T (enExample) |
| RS (1) | RS63426B1 (enExample) |
| SI (1) | SI3261640T1 (enExample) |
| SM (1) | SMT202200276T1 (enExample) |
| WO (1) | WO2016138138A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| DK3261640T3 (da) | 2015-02-25 | 2022-07-11 | Univ California | 5ht-agonister til behandling af epilepsilidelser |
| GB201620095D0 (en) * | 2016-11-28 | 2017-01-11 | Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And | Novel use |
| DK3800177T3 (da) | 2015-12-22 | 2025-03-31 | Zogenix International Ltd | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme |
| US10689324B2 (en) | 2015-12-22 | 2020-06-23 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| US10517841B1 (en) | 2018-06-14 | 2019-12-31 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| BR112020026099A2 (pt) | 2018-06-20 | 2021-03-23 | Lts Lohmann Therapie-Systeme Ag | sistema terapêutico transdérmico que contém asenapina |
| CN118806732A (zh) | 2018-06-20 | 2024-10-22 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| WO2020018839A1 (en) | 2018-07-18 | 2020-01-23 | The Regents Of The University Of California | Compounds and methods for synergistic activation of m channels |
| BR112021001135A2 (pt) * | 2018-07-27 | 2021-04-20 | Xenon Pharmaceuticals Inc. | compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico |
| WO2020105005A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| MX2021009037A (es) | 2019-01-30 | 2021-10-13 | Diamond Therapeutics Inc | Composiciones y metodos para el manejo de trastornos. |
| CA3141688A1 (en) * | 2019-05-29 | 2020-12-03 | The Regents Of The University Of California | Methods and compositions for treating epilepsy |
| EP3791873A1 (en) * | 2019-09-16 | 2021-03-17 | Universite De Bordeaux | Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies |
| CA3155618A1 (en) * | 2019-10-23 | 2021-04-29 | Jed Hubbs | Treatment of epileptic conditions with gabaa receptor modulators |
| CA3158781A1 (en) * | 2019-10-23 | 2021-04-29 | Michael Wood | Methods of treating the symptoms of autism spectrum disorder |
| KR20210054684A (ko) | 2019-11-06 | 2021-05-14 | 동국대학교 경주캠퍼스 산학협력단 | 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| AU2020395254B2 (en) * | 2019-12-06 | 2026-04-02 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| KR102476771B1 (ko) * | 2020-05-08 | 2022-12-13 | 광운대학교 산학협력단 | 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| IL307194A (en) * | 2021-03-25 | 2023-11-01 | Maplight Therapeutics Inc | Pharmaceutical compositions comprising zolmitriptan |
| CN117750957A (zh) * | 2021-03-25 | 2024-03-22 | 地图之光治疗股份有限公司 | 包含佐米曲坦的药物组合物 |
| CA3221934A1 (en) * | 2021-06-01 | 2022-12-08 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| CA3221395A1 (en) * | 2021-06-10 | 2022-12-15 | Neurelis, Inc. | Methods and compositions for treating seizure disorders in pediatric patients |
| US20250120951A1 (en) * | 2021-07-30 | 2025-04-17 | Epygenix Therapeutics, Inc. | Clemizole formulation |
| WO2023107965A1 (en) * | 2021-12-06 | 2023-06-15 | Terran Biosciences, Inc. | Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc) |
| US11974992B2 (en) | 2022-01-26 | 2024-05-07 | Neurolixis | Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy |
| WO2023144166A1 (en) | 2022-01-26 | 2023-08-03 | Neurolixis | Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy |
| US20250295611A1 (en) * | 2022-04-27 | 2025-09-25 | Tessellate Therapeutics Inc. | Methods of treating 5ht2a receptor-mediated conditions |
| CA3247344A1 (en) | 2022-06-09 | 2023-12-14 | Diamond Therapeutics Inc. | AMORPHIC PSILOCYBIN (A-POLYMORPHIC) |
| WO2024118280A1 (en) * | 2022-11-30 | 2024-06-06 | Mind Medicine, Inc. | 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action |
| WO2026112377A1 (en) * | 2024-11-20 | 2026-05-28 | Intra-Cellular Therapies, Inc. | Pharmaceutical compositions and methods |
| CN119564685B (zh) * | 2024-12-16 | 2026-02-06 | 中国人民解放军军事科学院军事医学研究院 | Yl-0919在癫痫或癫痫导致的脑损伤治疗中的应用 |
| CN122124198B (zh) * | 2026-04-29 | 2026-07-31 | 湖北健肽生物科技有限公司 | 一种具有改善肠胃功能的小麦低聚肽的制备方法及应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2436883C2 (de) | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
| AU2002259130A1 (en) | 2001-05-03 | 2002-11-18 | Eli Lilly And Company | Agents for treatment of hcv and methods of use |
| US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| US7582428B2 (en) | 2003-08-22 | 2009-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-HCV agents |
| US20050215589A1 (en) * | 2003-09-03 | 2005-09-29 | Roger Crossley | Inhibitors of 5-HT2A receptor |
| EP1787679A1 (en) * | 2005-07-29 | 2007-05-23 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| US7635710B2 (en) | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US8642351B2 (en) | 2006-09-20 | 2014-02-04 | Waters Technologies Corporation | Apparatus and methods of fluid chromatography |
| EP2134556B1 (en) | 2007-04-06 | 2012-07-18 | Koninklijke Philips Electronics N.V. | Air pollution sensor system |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| US20110009351A1 (en) | 2007-05-09 | 2011-01-13 | Traffick Therepeutics Inc. | Screening assay to identify correctors of protein trafficking defects |
| WO2009039248A2 (en) | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection |
| KR100925176B1 (ko) | 2007-09-21 | 2009-11-05 | 한국전자통신연구원 | 지리 정보를 이용한 네트워크 상태 표시장치 및 방법 |
| MX2010009110A (es) * | 2008-02-19 | 2010-11-30 | Adolor Corp | Beloxepina, sus enantiomeros, y analogos de la misma para el tratamiento de dolor. |
| JP2011518154A (ja) | 2008-04-16 | 2011-06-23 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （ｒ）−１−｛２−［４’−（３−メトキシプロパン−１−スルホニル）−ビフェニル−４−イル］−エチル｝−２−メチル−ピロリジンの合成に有用なプロセス |
| CN102088990A (zh) | 2008-05-16 | 2011-06-08 | 阿尔伯维塔公司 | 癫痫的治疗 |
| US20110217265A1 (en) | 2008-09-23 | 2011-09-08 | Glenn Jeffrey S | Screening for Inhibitors of HCV Amphipathic Helix (AH) Function |
| CN102448458B (zh) | 2009-03-18 | 2015-07-22 | 小利兰·斯坦福大学理事会 | 治疗黄病毒科病毒感染的方法和组合物 |
| EP2408448A4 (en) | 2009-03-18 | 2012-09-19 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
| WO2010132691A1 (en) | 2009-05-13 | 2010-11-18 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
| CN102666537A (zh) | 2009-10-20 | 2012-09-12 | 艾格尔生物制药股份有限公司 | 治疗黄病毒科病毒感染的氮杂吲唑 |
| US20150313913A1 (en) | 2013-02-05 | 2015-11-05 | University Of Washington Through Its Center For Commercialization | Positive allosteric modulators of the gaba-a receptor in the treatment of autism |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| DK3035926T3 (da) * | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| WO2015066344A1 (en) * | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN104936947B (zh) | 2013-12-27 | 2017-03-08 | 杭州普晒医药科技有限公司 | 氯卡色林盐及其晶体、其制备方法和用途 |
| DK3261640T3 (da) | 2015-02-25 | 2022-07-11 | Univ California | 5ht-agonister til behandling af epilepsilidelser |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2016
- 2016-02-24 DK DK16756282.6T patent/DK3261640T3/da active
- 2016-02-24 US US15/552,784 patent/US10874643B2/en active Active
- 2016-02-24 EP EP19211183.9A patent/EP3632434A1/en not_active Withdrawn
- 2016-02-24 SM SM20220276T patent/SMT202200276T1/it unknown
- 2016-02-24 ES ES22157142T patent/ES3060954T3/es active Active
- 2016-02-24 WO PCT/US2016/019368 patent/WO2016138138A1/en not_active Ceased
- 2016-02-24 CN CN202111041649.4A patent/CN113546174A/zh active Pending
- 2016-02-24 EP EP22157142.5A patent/EP4043016B1/en active Active
- 2016-02-24 SI SI201631545T patent/SI3261640T1/sl unknown
- 2016-02-24 EA EA201992474A patent/EA201992474A3/ru unknown
- 2016-02-24 LT LTEPPCT/US2016/019368T patent/LT3261640T/lt unknown
- 2016-02-24 KR KR1020177026528A patent/KR102385665B1/ko active Active
- 2016-02-24 EP EP25211402.0A patent/EP4696377A3/en active Pending
- 2016-02-24 PT PT167562826T patent/PT3261640T/pt unknown
- 2016-02-24 BR BR112017018297-1A patent/BR112017018297B1/pt active IP Right Grant
- 2016-02-24 JP JP2017544887A patent/JP6884703B2/ja active Active
- 2016-02-24 CA CA2977135A patent/CA2977135C/en active Active
- 2016-02-24 HR HRP20220822TT patent/HRP20220822T1/hr unknown
- 2016-02-24 EA EA201791882A patent/EA201791882A1/ru unknown
- 2016-02-24 ES ES16756282T patent/ES2920886T3/es active Active
- 2016-02-24 KR KR1020237037303A patent/KR20230152844A/ko active Pending
- 2016-02-24 PL PL16756282.6T patent/PL3261640T3/pl unknown
- 2016-02-24 RS RS20220598A patent/RS63426B1/sr unknown
- 2016-02-24 EP EP16756282.6A patent/EP3261640B1/en active Active
- 2016-02-24 CN CN201680023991.2A patent/CN107530326B/zh active Active
- 2016-02-24 CA CA3204599A patent/CA3204599A1/en active Pending
- 2016-02-24 KR KR1020227011498A patent/KR20220048045A/ko not_active Ceased
- 2016-02-24 HU HUE16756282A patent/HUE059559T2/hu unknown
- 2016-02-24 AU AU2016222804A patent/AU2016222804C1/en active Active
-
2019
- 2019-11-08 US US16/679,112 patent/US11648237B2/en active Active
-
2020
- 2020-05-01 JP JP2020081127A patent/JP2020143087A/ja active Pending
- 2020-10-28 US US17/082,929 patent/US20210154171A1/en active Pending
-
2021
- 2021-06-23 AU AU2021204261A patent/AU2021204261B2/en active Active
- 2021-08-05 JP JP2021128790A patent/JP7846506B2/ja active Active
-
2022
- 2022-05-16 AU AU2022203274A patent/AU2022203274B2/en active Active
- 2022-06-06 JP JP2022091363A patent/JP2022116307A/ja active Pending
- 2022-06-22 CY CY20221100428T patent/CY1125360T1/el unknown
-
2023
- 2023-03-30 US US18/192,955 patent/US12447144B2/en active Active
- 2023-09-29 JP JP2023169390A patent/JP2024009839A/ja active Pending
-
2025
- 2025-05-29 US US19/222,750 patent/US20260083706A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240041848A1 (en) | Methods and compositions for treating herpesvirus induced conditions | |
| US11072648B2 (en) | Mast cell stabilizers for treatment of fever | |
| JP2022153638A5 (enExample) | ||
| HRP20220822T1 (hr) | 5ht agonisti za liječenje poremećaja epilepsije | |
| CN103764133A (zh) | 克仑特罗在治疗自闭症上的用途 | |
| WO2012056246A1 (en) | Combination treatment of major depressive disorder | |
| Bang et al. | Paroxetine controlled release | |
| US20110039926A1 (en) | Use of enantiomer (1s, 2r) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients | |
| US20070276046A1 (en) | Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents | |
| JP2011157395A5 (enExample) | ||
| JP7312286B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| Suvar | Antidepressants | |
| TW200940049A (en) | Associations for obtaining medicaments for the treatment of bipolar disorders | |
| JP2007513095A5 (enExample) | ||
| Bhagat et al. | Nabilone: A Synthetic Cannabinoid in Postoperative Nausea and Vomiting | |
| Nedić et al. | Rapidity in reducing depressive symptomatology: Moclobemide vs amitriptyline | |
| HK1254168B (en) | Combinations of a nucleoside analog and an inducing agent for use in treating herpesvirus-induced conditions | |
| JP2007508242A (ja) | トロンボキサンａ２受容体アンタゴニストとシクロオキシゲネーゼ−１の阻害剤との組み合わせを伴う組成物および方法 | |
| HK40011695B (en) | Norketotifen for treatment of hypercytokinemia and viral infections | |
| HK40011695A (en) | Norketotifen for treatment of hypercytokinemia and viral infections |